What Is Pterostilbene and What Are Its Benefits?

Learn about pterostilbene, a polyphenol related to resveratrol, and how its distinct molecular structure influences its bioavailability and function in the body.

Pterostilbene is a naturally occurring plant compound found most abundantly in blueberries, with smaller amounts in grapes, peanuts, and certain other plants. It belongs to the stilbene family and is chemically very close to resveratrol, the polyphenol famously associated with red wine. The key difference is structural: pterostilbene has two methoxy groups where resveratrol has hydroxyl groups, making it more fat-soluble and far better absorbed by the body. That single chemical tweak has made it the subject of growing research interest, with studies exploring its antioxidant, anti-inflammatory, metabolic, and even anticancer potential.

Where Pterostilbene Comes From

Plants produce pterostilbene as a defense compound. When grapevines are infected by pathogens, for instance, they ramp up production of stress metabolites including pterostilbene as part of their immune response. Blueberries are the richest dietary source, though the concentrations are still quite small. You would need to eat a substantial quantity of blueberries daily to reach the doses used in research studies, which is why supplementation has become the more practical route for anyone interested in its effects. Peanuts and grapes also contain pterostilbene, but in lower amounts.

How It Compares to Resveratrol

If you have heard of resveratrol, pterostilbene is essentially its more bioavailable sibling. Both compounds share a similar stilbene backbone and overlap in their biological activities, including antioxidant, anti-inflammatory, neuroprotective, and cardioprotective properties. The practical difference comes down to how much of the compound your body can actually use after you swallow it.

In a head-to-head pharmacokinetic study in rats, resveratrol was roughly 20% bioavailable while pterostilbene came in around 80%. After an oral dose, plasma levels of pterostilbene and its metabolites were markedly higher than those of resveratrol and its metabolites. The reason is straightforward: those two methoxy groups make pterostilbene more lipophilic, meaning it crosses cell membranes more easily and resists rapid breakdown in the gut and liver. This matters because a compound that gets destroyed before it reaches your tissues cannot do much good, regardless of how promising it looks in a petri dish.

The bioavailability advantage also shows up in direct comparisons of biological activity. In colon cancer cell lines, pterostilbene produced stronger effects on cell death at the same concentration as resveratrol, and researchers attributed the difference at least partly to its superior absorption. In a skin study, topically applied pterostilbene effectively prevented chronic UV-induced skin cancer in hairless mice while resveratrol did not. Scoping reviews of the skin photoaging literature have concluded that pterostilbene has the potential to outperform resveratrol for skin protection, owing to its chemical structure advantages.

Antioxidant and Anti-Inflammatory Properties

Much of the excitement around pterostilbene centers on its behavior as an antioxidant and anti-inflammatory agent, which are two closely related processes. On the antioxidant side, pterostilbene activates a cellular defense pathway centered on a protein called Nrf2, which acts as a master switch for the body’s own antioxidant enzymes. When Nrf2 moves into the cell nucleus, it turns on genes that produce protective enzymes. In cell studies, pterostilbene increased these antioxidant enzymes in a dose-dependent manner, and when researchers knocked out Nrf2, the protective effects largely disappeared. This tells us the Nrf2 pathway is central to how pterostilbene works, not just a bystander. The compound also engages other redox-sensitive processes, including mitochondrial stress responses and metabolic regulation pathways.

On the inflammation side, pterostilbene tamps down the NF-κB pathway, which is one of the body’s primary inflammatory signaling cascades. In mouse models fed high-fat diets, pterostilbene suppressed the inflammatory response by inactivating NF-κB signaling. In brain endothelial cell lines, pterostilbene reduced inflammatory markers including IL-6 and TNF-α and protected against blood-brain barrier disruption, again by inhibiting the NF-κB pathway. Reviews of the broader evidence describe pterostilbene’s influence on multiple regulatory pathways, including PI3K/Akt, as part of its diverse anti-inflammatory strategy.

What the Human Clinical Data Actually Shows

Here is where a healthy dose of realism is warranted. The vast majority of pterostilbene research has been done in cells, rodents, or other animal models. The human evidence is thin. There are really only a handful of clinical trials, and most of them are small. The one that gets cited most often is a randomized, double-blind, placebo-controlled trial that tested pterostilbene at two doses (50 mg twice daily and 125 mg twice daily) in adults with high cholesterol.

The results were mixed and worth knowing about before you buy a supplement. On the positive side, the high-dose group saw a meaningful drop in blood pressure, and the effect appeared to be dose-dependent. On the less encouraging side, LDL cholesterol actually went up with pterostilbene taken alone, rising about 17 mg/dL on average across both dose groups. When pterostilbene was combined with grape extract, that LDL bump was not significant, and patients already on cholesterol medication also seemed protected from the increase. There was no significant change in triglycerides. So the cardiovascular picture from human data is genuinely complicated: blood pressure improved, but cholesterol moved in the wrong direction when taken as a standalone supplement.

A separate safety-focused analysis from a human clinical trial concluded that pterostilbene was generally safe at doses up to 250 mg per day, with no adverse effects on liver function, kidney markers, or blood glucose. That is reassuring as far as safety goes, but “safe” and “effective” are different claims. We have reasonable confidence that pterostilbene supplements will not harm you at typical doses, but the proof that they reliably deliver the benefits seen in animal studies remains incomplete.

Metabolic Health and Blood Sugar

Animal research on pterostilbene and metabolic health has been more consistently encouraging than the cholesterol data in humans. In rat models of type 2 diabetes induced by fructose feeding, pterostilbene treatment improved insulin sensitivity and glycemic control while reducing oxidative stress in the liver. Another rat study found that pterostilbene restored blood glucose, lipid profiles, and antioxidant levels, while also reducing insulin resistance and inflammatory markers in diabetic animals with depression-like behavior.

The metabolic benefits in animals seem to overlap with the antioxidant and anti-inflammatory mechanisms described earlier. High blood sugar and insulin resistance create a cycle of oxidative stress and chronic low-grade inflammation, and pterostilbene appears to intervene in both. Whether those animal results translate to meaningful improvements in people with prediabetes or type 2 diabetes remains an open question, and no large-scale human trial has specifically tested that yet.

Cancer Research in the Lab

Pterostilbene’s anticancer properties are among the most studied in preclinical settings. In breast cancer cell lines, pterostilbene inhibited tumor growth both in cell culture and in live animal models, triggering cell death and halting the cell division cycle. In a mouse model of lung squamous cell carcinoma, pterostilbene treatment significantly reduced cell proliferation and increased markers of programmed cell death, with the higher dose showing stronger effects. And in the colon cancer comparison mentioned earlier, pterostilbene outperformed resveratrol at the same concentration in triggering cancer cell death.

This is the kind of data that generates headlines but deserves careful framing. Killing cancer cells in a dish or slowing tumors in mice is an important first step in drug development, but the graveyard of compounds that worked beautifully in rodents and failed in human trials is enormous. No clinical trial has demonstrated that pterostilbene supplements prevent or treat cancer in people. The preclinical work is promising enough that it justifies continued research, but it does not justify taking pterostilbene with the expectation of cancer protection.

Skin Protection From UV Damage

One of the more striking findings in pterostilbene research involves its effects on skin exposed to ultraviolet radiation. When applied topically to hairless mice, pterostilbene prevented the acute effects of UV exposure, including increased skin thickness, redness, and wrinkling. More dramatically, in a six-month chronic UV exposure study, 90% of pterostilbene-treated mice did not develop skin cancers, while every control animal did. Resveratrol failed to provide this protection.

The mechanism appears to involve the same Nrf2 antioxidant pathway that drives pterostilbene’s other protective effects. In human skin cell cultures, pterostilbene shielded cells from UV-induced damage and boosted DNA repair activity through a PI3K-dependent activation of Nrf2. When researchers blocked either Nrf2 or PI3K, the protective effects were abolished. This has obvious implications for skincare, though again these are animal and cell studies. Some cosmetic companies have already started incorporating pterostilbene into topical products based on this data, but human skin trials are still lacking.

Pterostilbene and the Gut Microbiome

A newer area of research connects pterostilbene to changes in gut bacteria composition. In obese Zucker rats, pterostilbene supplementation shifted intestinal bacteria toward a healthier microbial profile, with increased abundance of certain beneficial genera including Akkermansia, a mucin-degrading bacterium that has been associated with metabolic health. The researchers suggested that some of pterostilbene’s anti-obesity effects could be mediated through these microbial shifts.

Across a range of animal and cell-based disease models, researchers have observed consistent shifts in microbial profiles following pterostilbene supplementation. These changes are thought to contribute to the compound’s health-promoting properties, particularly around immune regulation and disease prevention. The gut microbiome connection is interesting because it suggests pterostilbene may have effects beyond what you would predict from its direct antioxidant and anti-inflammatory activity alone. It also raises the possibility that the compound’s benefits depend partly on your existing gut bacteria, which varies enormously from person to person.

The NAD+ Connection and Aging Research

Pterostilbene has gained commercial visibility through its pairing with nicotinamide riboside, a precursor to NAD+, a molecule involved in energy metabolism and cellular repair that declines with age. The combination, marketed under the brand name Basis, has been tested in two clinical trials. In a study of 120 healthy adults aged 60 to 80, the combination at its recommended dose raised NAD+ levels by roughly 40% after four weeks, and a double dose raised them by about 90%. These increases held steady over the full eight-week trial, and no serious adverse events were reported.

A separate trial in patients with acute kidney injury found that the same combination raised NAD+ levels by about 37% at 48 hours, with no changes in kidney function, liver enzymes, or blood counts. A few patients reported minor gastrointestinal side effects. It is worth noting that these studies measured a biomarker (NAD+ levels), not a clinical outcome like living longer or getting fewer diseases. Whether boosting NAD+ translates to meaningful anti-aging benefits in humans is still an active and unresolved question.

In animal models, pterostilbene has been reported to increase lifespan, which researchers attribute to its antioxidant and anti-inflammatory properties as well as its ability to activate sirtuins and other longevity-associated pathways. In obese mice, pterostilbene enhanced heat production and mitochondrial generation through sirtuin-dependent mechanisms. The mouse brain hemorrhage model also found that pterostilbene activated sirtuin-mediated Nrf2 pathways, suggesting the neuroprotective and antioxidant effects are interconnected.

Practical Considerations for Supplement Users

If you are considering a pterostilbene supplement, here is what the current evidence supports. The compound appears safe at doses up to 250 mg per day based on the available human safety data. Most commercial supplements contain between 50 and 150 mg per capsule, which falls within this range. The compound is well absorbed, with far higher oral bioavailability than resveratrol.

The LDL cholesterol increase seen in the clinical trial is the most important caveat for anyone with cardiovascular risk factors. If you already have high cholesterol or are not on a statin, taking pterostilbene alone could move your LDL in the wrong direction. The combination with grape extract appeared to blunt this effect in the trial, though the study was small and the mechanism is unclear. If you have lipid concerns, monitoring your cholesterol while supplementing would be sensible.

The broader issue is the gap between the animal data and human evidence. Pterostilbene has an impressive preclinical profile across a wide range of conditions, including metabolic disease, neurodegeneration, cancer, and skin aging. But “impressive in mice” is a necessary early step, not a guarantee of human benefit. The supplement industry often sells compounds at this stage of evidence as though the case is closed, when in reality it is just getting started. Pterostilbene is one of the more plausible candidates to eventually deliver on its preclinical promise, largely because its high bioavailability solves the problem that sinks many polyphenols. But plausible is not proven, and the honest state of the science is that we are still waiting for the human outcome trials that would settle the question.